[96a5a0]: / output / allTrials / identified / NCT05301062_identified.json

Download this file

303 lines (303 with data), 12.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
{
"info": {
"nct_id": "NCT05301062",
"official_title": "China Radium-223 Safety and Effectiveness stuDy In Real World mCRPC paTients",
"inclusion_criteria": "* Male patient\n* Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases\n* No visceral metastases\n* Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment in the study as per investigator's routine treatment practice\n* Signed informed consent\nHealthy volunteers allowed\nMust be MALE",
"exclusion_criteria": "* Patients previously treated with Radium-223 for any reason\n* Patients currently treated in any other clinical trials including other Radium-223 studies\n* Patients are planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use\n* Participation in an investigational program with interventions outside of routine clinical practice\n* Patients previously treated with Docetaxel\n* Patients under treatment with Abiraterone Acetate and the Corticosteroids Prednisone or Prednisolone\n\nBesides Inclusion and exclusion criteria, sites should also follow the locally approved Radium-223 product information",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Male patient",
"criterions": [
{
"exact_snippets": "Male patient",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "* Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "adenocarcinoma confirmation method",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "castration resistant adenocarcinoma of the prostate",
"criterion": "adenocarcinoma type",
"requirements": [
{
"requirement_type": "resistance",
"expected_value": "castration resistant"
}
]
},
{
"exact_snippets": "adenocarcinoma of the prostate",
"criterion": "adenocarcinoma location",
"requirements": [
{
"requirement_type": "location",
"expected_value": "prostate"
}
]
},
{
"exact_snippets": "bone metastases",
"criterion": "metastasis location",
"requirements": [
{
"requirement_type": "location",
"expected_value": "bone"
}
]
}
]
},
{
"line": "* No visceral metastases",
"criterions": [
{
"exact_snippets": "No visceral metastases",
"criterion": "visceral metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment in the study as per investigator's routine treatment practice",
"criterions": [
{
"exact_snippets": "Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment",
"criterion": "Radium-223 treatment decision",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "prior to patient enrollment"
}
]
}
]
},
{
"line": "* Signed informed consent",
"criterions": [
{
"exact_snippets": "Signed informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients previously treated with Radium-223 for any reason",
"criterions": [
{
"exact_snippets": "Patients previously treated with Radium-223",
"criterion": "previous treatment with Radium-223",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients currently treated in any other clinical trials including other Radium-223 studies",
"criterions": [
{
"exact_snippets": "Patients currently treated in any other clinical trials",
"criterion": "current treatment in clinical trials",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "including other Radium-223 studies",
"criterion": "current treatment in Radium-223 studies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients are planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use",
"criterions": [
{
"exact_snippets": "systemic concomitant use of other radiopharmaceuticals",
"criterion": "use of radiopharmaceuticals",
"requirements": [
{
"requirement_type": "planned",
"expected_value": true
}
]
},
{
"exact_snippets": "treatment of prostate cancer",
"criterion": "prostate cancer",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* Participation in an investigational program with interventions outside of routine clinical practice",
"criterions": [
{
"exact_snippets": "Participation in an investigational program",
"criterion": "participation in investigational program",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "interventions outside of routine clinical practice",
"criterion": "interventions outside of routine clinical practice",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients previously treated with Docetaxel",
"criterions": [
{
"exact_snippets": "Patients previously treated with Docetaxel",
"criterion": "Docetaxel treatment",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients under treatment with Abiraterone Acetate and the Corticosteroids Prednisone or Prednisolone",
"criterions": [
{
"exact_snippets": "Patients under treatment with Abiraterone Acetate",
"criterion": "Abiraterone Acetate treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Corticosteroids Prednisone or Prednisolone",
"criterion": "Corticosteroid treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"Prednisone",
"Prednisolone"
]
}
]
}
]
},
{
"line": "Besides Inclusion and exclusion criteria, sites should also follow the locally approved Radium-223 product information",
"criterions": [
{
"exact_snippets": "sites should also follow the locally approved Radium-223 product information",
"criterion": "Radium-223 product information",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": "locally approved"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}